Data as of Q4 2025 (Dec 31, 2025)

Lynx1 Capital Management LP

โ€ขCIK: 1910456โ€ขFiling: Q4 2025

**Lynx1 Capital Management LP** manages $494M across a focused portfolio of 22 positions. The fund exhibits significant concentration in its top holdings, led by STOK at $171.5M and STT-PG at $132.2M. Further substantial allocations include CGEM ($92.8M) and DNLI ($28.7M). This structure suggests a conviction-driven, concentrated approach to generating alpha.

Total AUM
$494.0M
QoQ Performance
+0.6%
Positions
22
Top 10 Concentration
97.2%
Latest Filing
Q4 2025

Top Holdings Allocation

STOK
GHRS
CGEM
DNLI
STOK34.7%
GHRS26.8%
CGEM18.8%
DNLI5.8%
CCCC2.7%
XNCR2.2%
IMMATICS2.0%
TCRX1.6%

๐Ÿ“ˆ Biggest Buys

CGEM
CULLINAN THERAPEUTICS INC
+55.5%
18.8% of portfolio
DNLI
DENALI THERAPEUTICS INC
+564.4%
5.8% of portfolio
GHRS
GH RESEARCH PLC
+21.0%
26.8% of portfolio
XNCR
XENCOR INC
NEW
2.2% of portfolio
โ€”
IMMATICS N.V
NEW
2.0% of portfolio

๐Ÿ“‰ Biggest Sells

DTIL
PRECISION BIOSCIENCES INC
-4.7%
0.8% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

2GH
MERUS N V
SOLD
$144.4M
PTGX
PROTAGONIST THERAPEUTICS INC
SOLD
$46.5M
โ€”
ADC THERAPEUTICS SA
SOLD
$5.3M
IBIO
IBIO INC
SOLD
$874.1K
ALLO
ALLOGENE THERAPEUTICS INC
SOLD
$677.2K

Changes from Q3 2025

NEW13 new positions
โ†‘5 increased
โ†“1 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023